Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06811805

Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI

The goal of this clinical trial is to assess the effect of RenalGuard Therapy in reducing the rates of Acute Kidney Injury (AKI) within 72 hours after cardiac surgery in patients at risk of developing Cardiac Surgery Associated AKI (CSA-AKI) compared to standard-of-care (SoC).

Participants will be randomized (1:1) to one of the two study groups. The Treatment study group will be managed with the RenalGuard System. The RenalGuard treatment will start after induction of anesthesiology and will run during surgery and for 6-7 hours in the Intensive Care Unit (ICU). The treatment will aim to achieve a urine rate above a predefined urine rate threshold. Patients in the control group will be managed based on the usual clinical practice in cardiac surgery centres as detailed in the recommendations for CSA-AKI prevention by accepted clinical guidelines.

For both study groups general anaesthesia, cardiopulmonary bypass (CPB) run and overall patient care will be based on SoC for cardiac surgery.

Patients will be followed up for up to 7 days post surgery or until discharge, which ever comes first.

Long-term follow up will be performed at 90 days post surgery.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Jessa Medica Center, Hasselt, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female and >18 years of age
  • Patient able to give written consent
  • Scheduled for the following non-emergent cardiac surgery procedure requiring CPB, isolated or in combination:
  • coronary artery bypass graft (CABG)
  • aortic valve replacement or repair alone, with or without aortic root repair
  • mitral, tricuspid, or pulmonic valve replacement or repair
  • simultaneous replacement of several cardiac valves
  • CABG with aortic, mitral, tricuspid, or pulmonic valve replacement or repair
  • Surgery on the aorta: aortic root and/ or ascending aorta
  • Atrial fibrillation (AF) ablation surgery if combined with other cardiac procedures.
  • Atrial septal defect (ASD) closure if combined with other cardiac procedures.
  • Excision of myxoma if combined with other cardiac procedures
  • Have at least one of the following risk factors for CSA-AKI:
  • CKD-EPI eGFR 20-59 mL/min/1.73 m²
  • Age ≥ 75 years
  • Undergoing combined surgery (e.g. CABG + Valve)
  • Logistic EuroScore of ≥5 or, Euroscore II of ≥4 or Society of Thoracic Surgeons (STS) Score ≥4
  • Left ventricular ejection fraction (LVEF) ≤ 35% by invasive or noninvasive diagnostic cardiac imaging performed within 90 days prior to surgery.
  • Insulin-requiring diabetes
  • Non-insulin-requiring diabetes with HbA1C ≥ 6.1% in the last 6 months
  • Preoperative anemia within 4 weeks of surgery

Exclusion criteria

  • Patient requiring emergency surgery
  • Surgery to be performed without CPB
  • Patient receiving furosemide at a dose>100 mg/day orally (or the equivalent dose of an alternative loop diuretic) in the last week
  • Patient who cannot be urethrally catheterize for any reason
  • Patients already dialysis dependent
  • Patients with CKD-EPI eGFR <20 mL/min/1.73 m²
  • Known or suspected AKI (KDIGO criteria) at the time of screening
  • Patients participating in another interventional drug or device study or have received an investigational drug or device treatment within the last 30 days
  • Pregnant patient, self-reported
  • Patients whose planned surgery to be performed under conditions of circulatory arrest or hypothermia with rectal temperature < 28°Celsius (82.4° Fahrenheit)
  • Patient with suspected or confirmed bacteraemia, endocarditis, or pyelonephritis at hospital admission
  • Patients with pneumonia, aspiration, or bilateral pulmonary infiltrates from an infectious aetiology reported on chest x-ray or CT scan in the last 7 days
  • Patients in cardiogenic shock or hemodynamic instability which require inotropes or vasopressors or other mechanical devices (Impella Heart Pump, IABP) within 24 hours prior to surgery
  • Patients on extracorporeal membrane oxygenation (ECMO) or durable ventricular assist device (VAD) at the time of screening, or planned use within 24h prior to surgery
  • Patients currently treated with chemotherapy or radiation therapy that may have an impact on kidney function.
  • Patient underwent prior solid organ transplantation
  • Patients underwent major surgery within the last 3 months
  • Any condition which, in the judgement of the investigator, might increase the risk to the patient.

Treatment and study plan

RenalGuard Therapy

Device

RenalGuard Therapy

Standard of Care (SOC)

Other

Standard of care

Primary outcomes

  1. CSA-AKI incidence between study groups

    Time frame: Within 72 hours

    CSA-AKI is defined as when any of the following three criteria are met:

    • An increase in serum creatinine (SCr) by ≥0.3 mg/dl (≥26.5 umol/l) within 72 hours compared to the baseline value; OR
    • An increase in SCr by ≥1.5 times from SCr value at baseline within 72 hours; OR
    • Use of Renal Replacement Therapy (RRT) within 7 days of surgery or by hospital discharge (whichever is the earliest)

Secondary outcomes

  1. A composite safety endpoint which includes: Significant severe clinically meaningful change in electrolytes (K+, Mg+2, Na+), New onset of postoperative atrial fibrillation, and Pulmonary edema

    Time frame: Within 72 hours

  2. CSA-AKI Stage

    Time frame: Within 72 hours

    CSA-AKI severity by stage distribution between the study groups

  3. CSA-AKI Incidence

    Time frame: Within 7 days

    AKI incidence within 7 days based on the KDIGO definition described in the primary endpoint section

  4. CSA-AKI Duration

    Time frame: Within 7 days

    Duration of AKI within 7 days of surgery

Other outcomes

  1. The incidence of Major Adverse Kidney Events (MAKE)

    Time frame: 90 days post-surgery

    MAKE-90 will be defined as:

    • Death within 90 days
    • Any dialysis within 90 days
    • A decrease of 25% in Estimate glomerular filtration rate (eGFR) from baseline eGFR level at 90 days
  2. ICU and in-hospital length of stay

    Time frame: 7 days

  3. Cumulative costs of ICU stay

    Time frame: 7 days

Sponsors and collaborators

Lead sponsor

CardioRenal Systems, Inc.

Industry

Registry information

Official study title

Post-Marketing Clinical Follow Up Study to Further Assess the Safety & Efficacy of RenalGuard® Therapy in the Prevention of Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI)

Acronym: KIDNEY-II

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Feb 6, 2025
Registry last updated
Jan 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.